- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Thomas P. Miller Expects a Flurry of Activity if SCOTUS Rules for Plaintiffs in King v. Burwell
Although there will be changes in the marketplace if the Supreme Court decision makes residents in states using HealthCare.gov ineligible for subsidies, it won't be anything that is irreversible, according to Thomas P. Miller, JD, resident fellow at the American Enterprise Institute.
The predictions of so-called "death spirals" in insurance markets in states on the federal exchange resulting from a Supreme Court decision in King v. Burwell for the plaintiffs may be overblown, according to Thomas P. Miller, JD, resident fellow at the American Enterprise Institute.
Although there will be changes in the marketplace if the Supreme Court decision makes residents in states using HealthCare.gov ineligible for subsidies, it won't be anything that is irreversible. Something will be done in the event of a decision favorable for King, whether it is the Obama administration reversing course or the state reviewing their options for exchanges.
"I think there will be a flurry of activity—after the first round of finger pointing and blame shifting in Congress—to actually being to work on something that neither side will have as their first choice but will end up being the compromise that they have to do because they don't have another alternative," Mr Miller said.
Health Care Utilization and Cost of Diagnostic Testing for Respiratory Infections
September 17th 2025Syndromic reverse transcriptase–polymerase chain reaction tests for respiratory infections were associated with lower health care resource utilization and costs, implicating potential for improved value in patient care.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
